Halozyme Therap

Q2 FY2026 EarningsQ2 FY26 performance significantly exceeded consensus across all primary financial metrics: revenue reached $481.0M (+19.6% vs. $402.3M expected) and diluted GAAP EPS was $1.90 (+28.7% vs. $1.48 expected). Growth was primarily driven by a 50% YoY surge in royalty revenue to $307.7M, led by the rapid uptake of VYVGART Hytrulo and DARZALEX SC, alongside a 156% increase in bulk enzyme sales. Operating income beat expectations by 17.9%, reaching $287.7M, while a new $1.0B share repurchase authorization through 2028 reinforces a robust capital return profile.